PharmaShots | Incisive News in 3 Shots

Subscribe Now

newamsterdam pharma

NewAmsterdam Pharma Reports the Completion of Patient Enrollment in P-III trial (BROOKYLN) of Obicetrapib for Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Reports the Completion of Patient Enrollment in P-III trial (BROOKYLN) of Obicetrapib for Heterozygous Familia...

April 25, 2023

NewAmsterdam Pharma Initiates P-II Dose-Finding Study of Obicetrapib for the Treatment of Dyslipidemia

NewAmsterdam Pharma Initiates P-II Dose-Finding Study of Obicetrapib for the Treatment of Dyslipidemia

October 6, 2022

NewAmsterdam Pharma to Go Public via FLAC SPAC Merger for ~$326M

NewAmsterdam Pharma to Go Public via FLAC SPAC Merger for ~$326M

July 26, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us